Your browser is no longer supported. Please, upgrade your browser.
Actavis plc
IndexS&P 500 P/E- EPS (ttm)-6.09 Insider Own0.20% Shs Outstand392.77M Perf Week-1.92%
Market Cap113.80B Forward P/E13.48 EPS next Y21.49 Insider Trans0.00% Shs Float391.69M Perf Month-2.26%
Income-1630.50M PEG- EPS next Q3.94 Inst Own66.20% Short Float1.64% Perf Quarter8.70%
Sales13.06B P/S8.71 EPS this Y-40.80% Inst Trans1.49% Short Ratio1.92 Perf Half Y21.34%
Book/sh106.67 P/B2.72 EPS next Y21.54% ROA-4.00% Target Price344.44 Perf Year39.45%
Cash/sh0.64 P/C453.39 EPS next 5Y16.48% ROE-8.00% 52W Range193.00 - 317.72 Perf YTD12.56%
Dividend- P/FCF57.82 EPS past 5Y-42.20% ROI-2.70% 52W High-8.81% Beta0.35
Dividend %- Quick Ratio1.00 Sales past 5Y36.10% Gross Margin51.70% 52W Low50.12% ATR6.38
Employees21600 Current Ratio1.40 Sales Q/Q46.00% Oper. Margin-7.20% RSI (14)45.26 Volatility2.96% 1.97%
OptionableYes Debt/Eq0.55 EPS Q/Q-224.70% Profit Margin-11.70% Rel Volume0.73 Prev Close282.86
ShortableYes LT Debt/Eq0.52 EarningsMay 11 BMO Payout- Avg Volume3.34M Price289.74
Recom1.60 SMA20-1.47% SMA50-2.46% SMA20012.10% Volume2,430,468 Change2.43%
Apr-15-15Reiterated Barclays Equal Weight $285 → $300
Mar-30-15Reiterated RBC Capital Mkts Top Pick $330 → $361
Mar-03-15Reiterated Deutsche Bank Buy $330 → $336
Feb-20-15Reiterated Argus Buy $310 → $340
Feb-19-15Reiterated RBC Capital Mkts Top Pick $325 → $330
Feb-19-15Reiterated Canaccord Genuity Buy $300 → $352
Jan-21-15Reiterated Deutsche Bank Buy $280 → $330
Jan-13-15Reiterated CRT Capital Buy $270 → $288
Nov-21-14Reiterated Argus Buy $285 → $310
Nov-20-14Reiterated RBC Capital Mkts Top Pick $291 → $323
Nov-18-14Reiterated UBS Buy $278 → $333
Nov-06-14Reiterated RBC Capital Mkts Top Pick $286 → $291
Sep-22-14Downgrade Barclays Overweight → Equal Weight $250 → $250
Aug-06-14Reiterated UBS Buy $237 → $254
Jul-02-14Reiterated CRT Capital Buy $245 → $275
Jun-27-14Initiated Canaccord Genuity Buy $275
May-12-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
May-01-14Reiterated CRT Capital Buy $230 → $245
Apr-28-14Reiterated National Alliance Securities Buy $246 → $259
Apr-17-14Initiated National Alliance Securities Buy $246
May-01-15 05:40PM  What's in Store for Prothena (PRTA) this Earnings Season? - Analyst Blog
04:25PM  Will Keryx (KERX) Disappoint This Earnings Season? - Analyst Blog
04:08PM  Are Drug Mergers In Their Final Act?
11:55AM  Is it a Miss for TrovaGene (TROV) This Earnings Season? - Analyst Blog
Apr-30-15 10:09AM  Teva Beats on Q1 Earnings by Wide Margin, Ups View - Analyst Blog
Apr-29-15 05:14PM  Will Endocyte (ECYT) Disappoint This Earnings Season? - Analyst Blog
05:13PM  Valeant Beats Q1 Views, Lifts Guidance, Loses CFO at Investor's Business Daily
04:24PM  Is Exelixis (EXEL) Likely to Report Narrower Loss in Q1? - Analyst Blog
04:08PM  Activist Fund Manager ETF Goes Live at
03:23PM  EU Needs New Drugs to Fight Antibiotic Resistance at
01:57PM  Valeant raises outlook after completing purchase of Salix
10:55AM  Valeant Beats Q1 Views, Lifts Guidance, But Loses CFO at Investor's Business Daily
08:02AM  Heavyweight Funds In A Pacquiao-Mayweather World at Investor's Business Daily
07:00AM  Hedge Funds Love These 5 Big Stocks -- but Should You? at TheStreet
Apr-28-15 09:06PM  Teva 1Q15 Earnings Preview: Profitability Drivers
04:15PM  Actavis and Medicines360 Announce Publication of ACCESS IUS Efficacy and Safety Study of LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception PR Newswire
04:10PM  Will BioMarin (BMRN) Top Earnings Again on Vimzim Sales? - Analyst Blog
03:41PM  Oracle, Amgen Latest to Issue Bonds to Fund Buybacks at
03:20PM  Will Teva's (TEVA) Earnings Streak Continue in Q1? - Analyst Blog
03:20PM  Will Celgene (CELG) Beat Q1 Earnings on Strong Sales? - Analyst Blog
03:17PM  Will Vertex (VRTX) Surprise with a Lower Loss in Q1? - Analyst Blog
02:31PM  Will AmerisourceBergen (ABC) Beat on Earnings Yet Again? - Analyst Blog
02:27PM  Will Gilead (GILD) Miss Q1 Earnings on Weak HCV Sales? - Analyst Blog
09:32AM  Selz Capitals Latest 13F Reveals New Position in Yahoo! Inc. (YHOO) & Bets on Industrials and Healthcare at Insider Monkey
03:49AM  Health Care Sector Leads in CFO Turnover at The Wall Street Journal
Apr-27-15 04:41PM  Will Hospira (HSP) Earnings Surprise Estimates in Q1? - Analyst Blog
04:13PM  Will Generics & Currency Hit Pfizer (PFE) Q1 Earnings? - Analyst Blog
03:04PM  Will Bristol-Myers (BMY) Earnings Streak Continue in Q1? - Analyst Blog
02:40PM  Will Epizyme (EPZM) Beat Estimates This Earnings Season? - Analyst Blog
01:42PM  Will Merck's (MRK) Q1 Earnings be Hit by Generics & Currency? - Analyst Blog
09:50AM  AstraZeneca Falls on Q1 Earnings Decline, Reiterates View - Analyst Blog
Apr-26-15 01:15PM  No end in sight to wave of pharma dealmaking at Financial Times
Apr-24-15 08:06PM  Endo International, a New Position for OZ Management
03:39PM  The Parade of Weak Earnings Reports Continues - Earnings Preview
01:07PM  Teva, Mylan and Perrigo: Which Combination is Most Likely? at
09:25AM  Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE┬« (dalbavancin) in the Treatment of ABSSSI PR Newswire
07:47AM  How trader draws income in Actavis
Apr-23-15 06:37PM  Orexigen's Obesity Drug Contrave Faces Generic Threat - Analyst Blog
08:00AM  Actavis Launches AVYCAZ (Ceftazidime-Avibactam) Anti-Infective In U.S. PR Newswire
12:36AM  Meet Pharmas Newest Movers and Shakers at The Wall Street Journal
Apr-22-15 09:22PM  Meet Pharma's Newest Movers and Shakers at The Wall Street Journal
05:09PM  Actavis PLC -- Moody's downgrades bonds of Allergan to Baa3 at Moody's
04:37PM  ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
03:48PM  Coatue Management Starts New Position in Actavis
02:11PM  Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
01:21PM  Teva Guides for Lower Revenues in 2015
01:20PM  Wall Street Expects Higher Teva Earnings per Share in 1Q15
Apr-21-15 05:30PM  Teva offers to buy Mylan in $40.1B cash-and-stock deal
04:08PM  Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
01:52PM  Teva seeks cushion against loss of patent protection at Financial Times
12:18PM  Adi Capitals Paritosh Gupta Beat the Market but Trailed His Wife in Q1 at Insider Monkey
Apr-20-15 04:15PM  Actavis Announces Retirement of Charles M. Mayr PR Newswire
08:00AM  Actavis Announces FDA Approval of Expanded Label for BOTOX┬« (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults PR Newswire
Apr-17-15 11:41PM  Research Reports at
06:06PM  Mylan dismisses takeover interest from Teva Pharmaceuticals at Financial Times
04:37PM  Global Worries Sink U.S. Stocks; Apple Breaches Support Level at Investor's Business Daily
04:06PM  Revenue Weakness Stands Out in Q1 Earnings Season - Earnings Preview
10:09AM  MylanPerrigo Merger: Expanding into Over-the-Counter Drugs
Apr-16-15 10:05AM  5 Must-See Stock Charts to Trade for Gains at TheStreet
10:04AM  Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail at TheStreet
09:17AM  Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast at noodls
09:00AM  Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast PR Newswire
08:45AM  Global Pharma Company Mylan Offers to Buy Perrigo
Apr-15-15 11:30AM  Teva, Actavis, Other Giants Set to Battle for Generics Space at TheStreet
10:08AM  Yankee Bonds Throng the High-Grade Primary Market
Apr-14-15 06:06PM  A House Divided? What Policymaker Views Mean for Investors
05:03PM  Missed A Leader's Breakout? How To Play A Second Pullback
01:27PM  Parents sue Botox maker after woman with cerebral palsy dies
11:06AM  Lone Pine Capital Sells Its Stake in Actavis
09:30AM  J.P. Morgan, Bank of America, Gilead Sciences and Actavis are part of Zacks Earnings Preview: - Press Releases
Apr-13-15 11:05PM  Magnetar Capital Raises Its Stake in Actavis
08:54PM  Actavis: No apologies for seeking Alzheimer's drug profits
04:33PM  ACTAVIS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
02:42PM  U.S. court weighs whether to let Actavis drop Alzheimer's drug Reuters
02:40PM  Q1 Earnings Season Ramps Up - Earnings Preview
10:47AM  Why Mylan, Teva and Perrigo are This Year's Valeant, Allergan and Actavis at
09:22AM  Actavis and Medicines360 Announce U.S. Availability of LILETTA (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years PR Newswire
09:21AM  Actavis Chairman Bisaro Joins Zoetis Board With Ackman Blessing at Bloomberg
Apr-10-15 05:31PM  If First Breakout Doesn't Work, Keep Watching For A New Rally
05:26PM  Shire's SHP625 Fails in Phase II, FDA Accepts Lifitegrast NDA - Analyst Blog
04:10PM  Permian Investment Partners Has A Thing or Two To Teach You About Investing at Insider Monkey
11:18AM  Actavis CEO: 'Very Few Banks Can Do What J.P. Morgan Can' at The Wall Street Journal
10:18AM  Tiger Ratan Trumps Hedge Fund Industry in Q1; See How Nehal Chopras Stock Picks Performed at Insider Monkey
09:38AM  Groupon Inc (GRPN), eBay Inc (EBAY), Sunedison Inc (SUNE): Billionaire Lee Coopermans Picks Edged The Market in Q1 at Insider Monkey
Apr-09-15 06:25PM  Specialty pharma; remember those two words: Cramer
05:22PM  Controversial Alzheimer's drugmaker tactic
04:55PM  Allergan drops lawsuit againt Valeant and Pershing Square at MarketWatch
04:52PM  Shire Up As Dry-Eye Drug Gets Early FDA Decision Date at Investor's Business Daily
04:06PM  Superbugs Turn Big Pharma, Gov't Focus To Antibiotics at Investor's Business Daily
02:40PM  Should Mylan Marry Perrigo Or Teva? Street Debates at Investor's Business Daily
01:00PM  Roche's Avastin's Label Expanded in EU for Cervical Cancer - Analyst Blog
12:46PM  Hedge fund machines cash in-again at CNBC
11:37AM  Allergan, Valeant, Pershing Square Settle Lawsuits at The Wall Street Journal
10:40AM  Actavis and Rhythm Start Mid-Stage Study on Relamorelin - Analyst Blog
10:37AM  The Winner In A Mylan-Perrigo Deal? Teva, Says Citi at
09:31AM  Billionaire Halvorsens Picks Dominated S&P 500 Index in Q1: Alibaba Group Holding Ltd (BABA), Valeant and More at Insider Monkey
Apr-08-15 06:36PM  Cramer: Instant wealth? The right way to do a deal at CNBC
04:59PM  Generic drugmaker Mylan offers $29 bln for Perrigo Reuters
02:40PM  Shire Reaches Agreement with the FDA for ADHD Candidate - Analyst Blog
12:33PM  Huge Losses in Alibaba Group Holding Ltd (BABA) Not Enough to Stop Billionaire Dan Loeb from Beating the Market at Insider Monkey
Actavis plc develops, manufactures, and sells generic, brand, and biosimilar pharmaceuticals. It offers over-the-counter products. The company also provides biosimilar products in women's health, oncology, and other therapeutic categories. In addition, it offers pharmaceutical products in the areas of urology, gastroenterology, and dermatology therapeutic categories. The company produces medicines in various formulations, including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids, and semi-solids. It sells its products in Ireland and internationally. Actavis plc was founded in 1983 and is based in Little Island, Ireland. The company has development and manufacturing facilities in Europe, the United States, and Asia.